Finjuve for Men: Hong Kong’s New Topical Finasteride Option
Finjuve for Men is a prescription topical finasteride spray for male androgenetic alopecia (AGA). The Hong Kong product contains finasteride 2.275 mg/mL and is designed to target DHT while substantially reducing systemic drug exposure compared with oral treatment.
Executive summary
Finjuve for Men is a prescription topical finasteride spray for male androgenetic alopecia (AGA). The Hong Kong product contains finasteride 2.275 mg/mL and is manufactured by Almirall Hermal GmbH. Its main proposition is oral-finasteride-like targeting of DHT while substantially reducing systemic drug exposure.
What exactly is Finjuve?
Attribute | Details |
|---|---|
Official name | Finjuve for Men Cutaneous Spray, Solution 2.275 mg/mL |
Active ingredient / form | Finasteride 2.275 mg/mL; cutaneous spray solution; 18 mL bottle |
Manufacturer | Almirall Hermal GmbH, Germany |
Hong Kong status | Prescription-only medicine; registration HK-68777. |
Approved indication | Treatment of male AGA/male-pattern hair loss, promoting hair growth and preventing further loss |
Finasteride selectively inhibits type-II 5-alpha-reductase, reducing conversion of testosterone to dihydrotestosterone (DHT), a major driver of follicular miniaturisation in AGA. Topical delivery produces high scalp exposure while lowering systemic exposure compared with oral treatment.
What does the clinical evidence show?
The pivotal Phase III study NCT03004469 / EudraCT 2015-002877-40 compared topical finasteride, vehicle placebo and oral finasteride 1 mg over 24 weeks. At week 24, adjusted target-area hair-count improvement was 20.2 hairs with topical finasteride versus 6.7 with placebo (P<0.001); oral finasteride produced a numerically similar 21.1-hair improvement. Maximum plasma finasteride concentrations were more than 100-fold lower topically, while serum DHT fell 34.5% versus 55.6% with oral treatment. Crucially, the trial was not designed to prove therapeutic equivalence to oral finasteride.
A subsequent Chinese Phase III trial, NCT05135468, randomised 270 men 2:1 to topical finasteride or placebo for 24 weeks and also demonstrated significantly greater hair growth with favourable tolerability. Cutia states that Chinese Phase I and III pivotal studies formed the principal basis of its regulatory package.
What are the safety issues?
Local pruritus and erythema may occur. Sexual adverse effects known with oral finasteride can still occur with Finjuve, although its lower systemic exposure is intended to reduce this risk. No treatment-related serious adverse events emerged in the pivotal Phase III study.
Finjuve is contraindicated for pregnancy/potential pregnancy exposure because finasteride may harm a male foetus. Formal interaction studies have not been performed; combining topical and oral finasteride lacks adequate evidence and should not be routine.
How does it compare with standard treatments?
Treatment | Evidence and dosing | Principal trade-off |
|---|---|---|
Finjuve | Once daily topical spray; superior to placebo at 24 weeks | Much lower systemic exposure; local irritation and residual systemic risk |
Finasteride oral | 1 mg daily; durable benefit demonstrated to five years | Extensive long-term evidence, but systemic sexual/mood risks |
Dutasteride oral | 0.5 mg daily; outperformed finasteride 1 mg in a 917-man, 24-week RCT | Inhibits type I and II 5-AR; greater systemic exposure; verify local AGA indication before use |
Finjuve therefore offers a plausible compromise for men wanting pharmacological DHT suppression but wishing to minimise systemic exposure; it should not be described as a risk-free oral finasteride replacement.
Patient FAQs
Is Finjuve simply a finasteride tablet turned into a spray?
No. It uses the same active drug but is a purpose-designed topical formulation producing markedly lower systemic exposure.
Does it work as well as oral finasteride?
Hair-count improvement was numerically similar in the pivotal trial, but formal equivalence was not established.
Can it still cause sexual side effects?
Yes. Lower exposure does not mean zero exposure or zero risk.
When might I see results?
Trials assessed improvement over approximately 12–24 weeks; treatment should be judged over months rather than days.
Can it be combined with minoxidil?
Potentially under medical supervision, but robust branded-Finjuve combination evidence is limited.
Can women use it?
It is indicated for male AGA, and pregnancy exposure is contraindicated.
Need Professional Consultation?
Our professional doctors will provide detailed hair and scalp analysis and develop personalized treatment plans.
Book Consultation Now